We are live on ! Find out more
LAB icon

Standard BioTools

141 hedge funds and large institutions have $543M invested in Standard BioTools in 2024 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 40 increasing their positions, 45 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 24 (+2)

13% more capital invested

Capital invested by funds: $480M → $543M (+$62.5M)

2.53% more ownership

Funds ownership: 73.23%75.76% (+2.5%)

5% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 22

2% less funds holding

Funds holding: 144141 (-3)

11% less repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 45

21% less call options, than puts

Call options by funds: $72K | Put options by funds: $91K

Holders
141
Holders Change
-3
Holders Change %
-2.08%
% of All Funds
2.02%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.06%
New
21
Increased
40
Reduced
45
Closed
22
Calls
$72K
Puts
$91K
Net Calls
-$19K
Net Calls Change
-$1.17M
Name Holding Trade Value Shares
Change
Change in
Stake
CC
1
Casdin Capital
New York
$138M +$14.3M +7,295,000 +11%
Viking Global Investors
2
Viking Global Investors
Connecticut
$113M
BlackRock
3
BlackRock
New York
$43.3M +$1.37M +699,108 +3%
Vanguard Group
4
Vanguard Group
Pennsylvania
$33.4M +$2.52M +1,288,934 +8%
Morgan Stanley
5
Morgan Stanley
New York
$29.4M +$4.53M +2,310,920 +18%
Sumitomo Mitsui Trust Group
6
Sumitomo Mitsui Trust Group
Japan
$18.5M -$2.08M -1,063,708 -10%
NAMA
7
Nikko Asset Management Americas
New York
$18.4M -$2.09M -1,069,779 -10%
AIM
8
ARK Investment Management
Florida
$17.3M -$7.3M -3,729,626 -29%
Millennium Management
9
Millennium Management
New York
$13.5M +$1.49M +762,239 +12%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$13.4M +$303K +154,848 +2%
TM
11
Tikvah Management
North Carolina
$12.6M
HBWM
12
Hollow Brook Wealth Management
New York
$10.7M +$10.8M +5,532,951 New
State Street
13
State Street
Massachusetts
$10.6M +$2.27M +1,157,984 +27%
Neuberger Berman Group
14
Neuberger Berman Group
New York
$9.13M +$1.16M +592,600 +14%
Barclays
15
Barclays
United Kingdom
$6.23M +$739K +377,195 +13%
Primecap Management
16
Primecap Management
California
$5.72M -$91.1K -46,520 -2%
Northern Trust
17
Northern Trust
Illinois
$5.08M +$3.19M +1,629,261 +163%
Charles Schwab
18
Charles Schwab
California
$4.72M +$3.13M +1,597,728 +189%
NFGH
19
Nan Fung Group Holdings
Hong Kong
$3.63M
SPC
20
Slate Path Capital
New York
$3.12M
Balyasny Asset Management
21
Balyasny Asset Management
Illinois
$1.91M -$12.6K -6,458 -0.6%
Goldman Sachs
22
Goldman Sachs
New York
$1.77M +$544K +277,559 +43%
JCP
23
Jennifer C. Price
$1.72M -$170K -86,818 -9%
PCP
24
Pacific Capital Partners
$1.59M +$147K +75,000 +10%
N
25
Nuveen
North Carolina
$1.59M +$77K +39,333 +5%

LAB Hedge Fund Activity: Q3 2024 in Review

141 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q3 2024, worth a combined $543M — up 13% from $480M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of LAB and 21 opened new positions — a net loss of 1 holder — while 45 trimmed existing stakes and 40 added.

The largest buyer was Casdin Capital, adding an estimated $14.3M. The largest seller was ARK Investment Management, cutting an estimated $7.3M.

  • 141 institutional investors held Standard BioTools (LAB) as of Q3 2024, down from 144 in Q2 2024.
  • Funds reported $543M of Standard BioTools stock for Q3 2024, up 13% quarter-over-quarter.
  • 21 funds opened new Standard BioTools positions in Q3 2024 and 22 closed out, a net change of -1 holder.
  • The largest Standard BioTools buyer in Q3 2024 was Casdin Capital, an estimated $14.3M added.
  • The largest Standard BioTools seller in Q3 2024 was ARK Investment Management, an estimated $7.3M sold.

Based on aggregated 13F filings for Q3 2024.